Core Insights - Akeso, Inc. has successfully included all five of its self-developed innovative drugs in the updated National Reimbursement Drug List (NRDL) for 2025, effective January 1, 2026, which enhances patient access to these treatments [1][2][3] Group 1: Drug Inclusion Details - All approved indications for Akeso's five independently commercialized drugs are now part of the NRDL, addressing major tumor diseases and autoimmune disorders prevalent in China [1][2] - Ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, has secured inclusion for its new first-line indication for PD-L1-positive non-small cell lung cancer (NSCLC), demonstrating a 49% reduction in disease progression or death compared to pembrolizumab in clinical trials [3][4] - Cadonilimab, another first-in-class bispecific antibody, has successfully negotiated inclusion for first-line indications in gastric and cervical cancers, showing significant clinical benefits across all patient populations [4] - Penpulimab has achieved NRDL inclusion for all four of its approved indications, including treatments for nasopharyngeal carcinoma and classical Hodgkin lymphoma [5] - Ebdarokimab, targeting IL-12/IL-23, has been included for the treatment of moderate-to-severe psoriasis, marking Akeso's first drug in the autoimmune disease sector [7] - Ebronucimab has secured inclusion for both of its approved indications related to hypercholesterolemia, enhancing its market presence [8] Group 2: Strategic Implications - The successful inclusion of these drugs in the NRDL is expected to reduce the financial burden on patients and provide superior treatment alternatives, thereby addressing significant public health challenges in China [2] - The recognition of these drugs in clinical practice prior to NRDL inclusion indicates their breakthrough clinical value and enhances trust among healthcare providers and patients [2] - This achievement lays a solid foundation for accelerating broader clinical adoption and supports Akeso's ongoing commercialization efforts, positioning the company for sustained growth and global expansion [2][3] Group 3: Company Overview - Akeso is a leading biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative biological medicines, with a robust pipeline of over 50 assets in various therapeutic areas [12] - The company utilizes an integrated R&D innovation system and has developed a comprehensive drug development platform, which includes bispecific antibody technology [12] - Akeso aims to provide affordable therapeutic antibodies globally while creating significant commercial and social value, striving to become a leading player in the biopharmaceutical industry [12]

Crescent Biopharma (:) Partnerships / Collaborations December 04, 2025 08:00 AM ET Company ParticipantsEllie Im - CMOJonathan McNeill - President and COOJan Pinkas - Chief Scientific OfficerAmy Reilly - Head of Investor RelationsJoshua Brumm - CEOConference Call ParticipantsRobert Driscoll - AnalystStephen Willey - AnalystEric Schmidt - AnalystNone - AnalystPhil Nadeau - AnalystNone - AnalystNone - AnalystOperatorWelcome to the Crescent Biopharma Conference Call. All participants will be in a listen-only mo ...

Core Insights - Akeso, Inc. has presented preclinical research data for its novel monoclonal antibody AK135, targeting IL-1RAP, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer [1][2] Group 1: Product Development - AK135 effectively targets IL-1RAP and blocks three key pro-inflammatory signaling pathways—IL-1, IL-33, and IL-36, providing significant pain relief in neuropathy with good tolerability and safety profiles [2][6] - The antibody is currently in Phase I clinical trials for treating chemotherapy-induced peripheral neuropathy (CIPN) [6][11] - Preclinical studies indicate that AK135 shows dose-dependent efficacy in alleviating neuropathic pain and maintains stable body weight in treated models without significant toxicity [8] Group 2: Market Context - CIPN affects 50-90% of chemotherapy-treated patients, with 30-40% progressing to chronic neuropathic pain, highlighting the clinical significance of effective treatment options [5] - Akeso's development of AK135 addresses a critical gap in treatment options for CIPN, as current effective therapies are limited [5][6] Group 3: Company Overview - Akeso is a leading biopharmaceutical company focused on innovative biological medicines, with a robust pipeline of over 50 innovative assets across various disease areas, including cancer and autoimmune diseases [11] - The company has developed a comprehensive end-to-end drug development platform and has 24 candidates in clinical trials, including 15 bispecific/multispecific antibodies [11]

Core Insights - Summit Therapeutics Inc. (NASDAQ:SMMT) is recognized as one of the best growth stocks under $25, particularly following the announcement of the expansion of its Phase 3 clinical development program for Ivonescimab [1][2] Company Overview - Summit Therapeutics Inc. is a biotechnology company focused on developing therapies primarily for cancer treatment [3] Clinical Development - The Phase 3 clinical program, named HARMONi-GI3, will evaluate Ivonescimab in combination with chemotherapy for patients with unresectable metastatic colorectal cancer [2] - The trial will compare the efficacy of Ivonescimab plus chemotherapy against bevacizumab plus chemotherapy as a first-line treatment for colorectal cancer [2] - The management aims to enroll approximately 600 patients globally, with trial sites in the United States expected to commence soon [2]

Core Insights - Summit Therapeutics Inc. reported progress on its lead drug candidate, ivonescimab, and its third-quarter financial results, with stock trading lower [1][7] Clinical Trial Results - The Phase 3 HARMONi-6 trial demonstrated that ivonescimab combined with chemotherapy reduced the risk of progression or death by 40% compared to BeOne Medicines' Tevimbra and chemotherapy for advanced squamous non-small cell lung cancer (NSCLC) [2] - The ivonescimab regimen extended the median time without tumor progression to 11.1 months, an increase of 4.2 months over the Tevimbra-based therapy [2] - The overall response rate (ORR) for ivonescimab plus chemotherapy was 75.9%, compared to 66.5% for tislelizumab plus chemotherapy, with a duration of response (DoR) of 11.20 months versus 8.38 months [3] Future Plans - Based on the HARMONi-6 results, the company plans to submit a Biologics License Application (BLA) for ivonescimab plus chemotherapy in Q4 2025 [4] - Summit is currently enrolling patients in the HARMONi-3 Phase 3 study to compare ivonescimab with Merck's Keytruda for first-line metastatic NSCLC, with expected completion of enrollment in the squamous cohort by H1 2026 [5] - A new Phase 3 HARMONi-GI3 study has been initiated for first-line unresectable metastatic colorectal cancer (CRC), with plans for further expansion of the ivonescimab clinical development program [6] Financial Position - As of September 30, 2025, the company reported cash and cash equivalents of $238.6 million [6]

Core Insights - Ivonescimab combined with chemotherapy demonstrated a 40% reduction in the risk of disease progression or death compared to Tislelizumab plus chemotherapy in the first-line treatment of patients with squamous non-small cell lung cancer (NSCLC) in the HARMONi-6 study [1][5][33] - The median progression-free survival (PFS) was 11.14 months for Ivonescimab plus chemotherapy versus 6.90 months for Tislelizumab plus chemotherapy, with a hazard ratio of 0.60 [1][5][6] - The safety profile of Ivonescimab was comparable to Tislelizumab, with similar rates of serious treatment-related adverse events (TRAEs) and discontinuation due to TRAEs [1][7][9] Study Overview - The HARMONi-6 trial was a Phase III, multi-center study conducted in China, evaluating Ivonescimab in combination with platinum-based chemotherapy against Tislelizumab plus chemotherapy in patients with advanced squamous NSCLC, regardless of PD-L1 expression [2][4][33] - The study was sponsored by Akeso, Inc., with all relevant data generated and analyzed by Akeso [2][4] Efficacy Results - Ivonescimab showed a statistically significant improvement in PFS, with a hazard ratio of 0.60 (95% CI: 0.46, 0.78; p<0.0001) [5][6] - The overall response rate (ORR) was 75.9% for Ivonescimab plus chemotherapy compared to 66.5% for Tislelizumab plus chemotherapy [6] - Duration of response (DoR) was also longer for Ivonescimab at 11.20 months versus 8.38 months for Tislelizumab [6] Safety Profile - The safety profile of Ivonescimab was manageable, with 3.4% of patients discontinuing due to TRAEs compared to 4.2% for Tislelizumab [9][11] - Serious TRAEs occurred in 32.3% of patients receiving Ivonescimab and 30.2% for Tislelizumab [11] - Grade 3 or higher immune-related adverse events were reported in 9.0% of Ivonescimab patients versus 10.2% for Tislelizumab [11] Future Studies - The HARMONi-3 global study will analyze squamous and non-squamous NSCLC cohorts separately, with enrollment completion expected in the first half of 2026 for the squamous cohort and the second half of 2026 for the non-squamous cohort [1][19][20] - An interim analysis for overall survival is planned for both cohorts upon reaching the prespecified number of events [19][20] Publication and Presentation - The results of the HARMONi-6 trial were published in The Lancet and presented at the European Society for Medical Oncology (ESMO) 2025 Congress [1][13][24]

Summary of China Biotech Outlook Industry Overview - The report focuses on the **China biotech industry**, particularly the performance of H-share listed companies in this sector, which has seen significant growth year-to-date (YTD) [1][2][3]. Key Performance Metrics - The average H-share EV/2030e sales multiple in the China biotech space has more than **doubled from 2.0x to 4.2x** YTD, surpassing the previous peak of **3.7x** in 2021 [3][21]. - The overall market cap of H-share listed China biotech companies has expanded by **154% YTD**, compared to **34%** for the Hang Seng Index (HSI) [9][19]. Market Drivers - The valuation re-rating is attributed to the **globalization of China biotech**, with increasing recognition of domestic drug developers' innovations [3][20]. - Anticipated **Fed rate cuts** are expected to boost investor risk appetite, particularly towards growth sectors like China biotech [4][9]. Stock Performance Insights - Stock performance will depend on fundamentals such as successful commercial execution and rapid innovation development [5][19]. - Companies with near-term catalysts (e.g., Akeso, InnoCare), proof-of-concept data (e.g., Keymed), and those positioned to leverage innovation trends (e.g., Innovent, Duality) are expected to outperform [5][19]. Risks and Challenges - Potential risks include persistent valuation premiums that may deter overseas investors and geopolitical tensions that could disrupt cross-border innovation flows [6][19]. Future Outlook - The report suggests that the sector will continue to be supported by the long-term thesis of **China drug innovation** becoming increasingly globalized [6][19]. - The expectation of higher valuations based on long-term forecasts (i.e., 2035e) could lead to further re-ratings across the sector [4][19]. Company-Specific Insights - **Abbisko Cayman Ltd**: Price target raised from **HK$8.30 to HK$22.00** [7][17]. - **Akeso, Inc.**: Price target increased from **HK$87.00 to HK$215.00** [7][17]. - **Duality Biotherapeutics Inc**: Price target raised from **HK$244.00 to HK$493.00** [7][17]. - **Everest Medicines Ltd**: Price target increased from **HK$40.00 to HK$55.00** [7][17]. - **HUTCHMED (China) Ltd**: Price target decreased from **US$18.00 to US$13.75** [7][17]. Valuation Trends - The report indicates a widening discount between Chinese biotech companies with in-house drug discovery capabilities and those relying on external sources [22][25]. - The current valuation band for the China biotech sector is approximately **3x-5x EV/sales**, aligning more closely with US biopharma companies [21][25]. Conclusion - The China biotech sector is at a pivotal inflection point, driven by domestic innovation and increasing global recognition. The anticipated Fed rate cuts and ongoing globalization trends are expected to further enhance the sector's attractiveness to investors [4][19][25].

Core Viewpoint - Summit Therapeutics Inc. (NASDAQ:SMMT) is identified as a promising stock for investment over the next three months, with a Buy rating and a price target of $40 initiated by Guggenheim [1][2]. Group 1: Stock Performance and Analyst Insights - The stock was previously favored when trading at $3 due to an overlooked progression-free survival readout for its drug Ivonescimab compared to Merck's Pembrolizumab in lung cancer [2]. - Currently trading at $24, the stock is still viewed positively, with expectations that successful outcomes in two first-line lung cancer trials could lead to significant price appreciation by 2027 and 2028 [2]. - Analysts project a 12-month average price target indicating a potential upside of 34.72% from current levels [3]. Group 2: Company Overview - Summit Therapeutics Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicinal therapies aimed at enhancing the quality and duration of life [3].

2025.8 Disclaimer This presentation has been delivered to interested parties for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase securities of Akeso, Inc. (the "Company"). This presentation does not constitute or contain an offer or invitation to sell, or any solicitation of any offer to subscribe for or purchase any securities in a ...

Core Viewpoint - The article discusses the significant investment by Bristol-Myers Squibb in the development of the cancer treatment drug BNT327, highlighting the rapid increase in its valuation and the potential for substantial returns in the innovative drug sector, particularly from Chinese companies [2][10]. Group 1: Drug Development and Valuation - Bristol-Myers Squibb has entered a partnership with BioNTech to develop and sell the dual-specific antibody BNT327, with an initial payment of $1.5 billion and potential total payments reaching $11.1 billion (approximately 800 billion RMB) [2]. - BNT327, originally developed by Chinese company Biotheus, was acquired by BioNTech for $1.055 billion, indicating a tenfold increase in its value within a year and a half [2]. - The dual-specific antibody targets both PD-1 and VEGF, enhancing immune response against tumors while inhibiting their blood supply, representing a significant advancement over traditional single-target therapies [6][8]. Group 2: Market Trends and Investment Opportunities - The innovative drug sector in China is experiencing a boom, with substantial investments and partnerships being formed, as evidenced by multiple large-scale deals in late 2024 [12][14]. - Notable transactions include GSK's $300 million upfront payment for a targeted therapy and other significant licensing agreements, indicating a strong market for innovative drugs [12]. - The Chinese biopharmaceutical industry is becoming increasingly attractive to global pharmaceutical companies, with a reported $45.5 billion in business development transactions in 2024, highlighting the competitive edge of Chinese drug developers [14][15].